{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:52:12Z","timestamp":1787503932712,"version":"build-2736575974"},"reference-count":50,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2025,8,3]]},"DOI":"10.1080\/14712598.2025.2522119","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T04:09:02Z","timestamp":1750133342000},"page":"811-819","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["An evaluation of bimekizumab for the treatment of hidradenitis suppurativa"],"prefix":"10.1080","volume":"25","author":[{"given":"Tomasz","family":"Skrzypczak","sequence":"first","affiliation":[{"name":"Specialist Medical Centre","place":["Polanica-Zdr\u00f3j, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Skrzypczak","sequence":"additional","affiliation":[{"name":"Citodent Dental Clinic","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Matusiak","sequence":"additional","affiliation":[{"name":"Wroclaw University of Science and Technology","place":["Wroclaw, Poland"]},{"name":"4th Military Hospital","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[{"name":"Wroclaw University of Science and Technology","place":["Wroclaw, Poland"]},{"name":"4th Military Hospital","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.16691"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16101"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000453259"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.09.008"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16677"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2015.08.002"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.6264"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.5114\/dr.2024.140820"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20472"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15412"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18983"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01894"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2343112"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.042"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00022-3"},{"key":"e_1_3_6_20_1","unstructured":"NOVARTIS. FDA approves Novartis cosentyx\u00ae as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade [Internet]. 2023 [cited 2025 May 22]. Available from: https:\/\/www.novartis.com\/news\/media-releases\/fda-approves-novartis-cosentyx-first-new-biologic-treatment-option-hidradenitis-suppurativa-patients-nearly-decade"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00906-2"},{"key":"e_1_3_6_22_1","unstructured":"UCB. FDA accepts supplemental biologics license applications for BIMZELX[\u00ae] (bimekizumab-bkzx) for moderate to severe hidradenitis suppurativa and additional 2mL device presentations [Internet]. 2024 [cited 2025 Mar 2]. Available from: https:\/\/www.ucb.com\/newsroom\/press-releases\/article\/fda-accepts-supplemental-biologics-license-applications-for-bimzelxr-bimekizumab-bkzx-for-moderate-to-severe-hidradenitis-suppurativa-and-additional-2ml-device-presentations"},{"key":"e_1_3_6_23_1","unstructured":"UCB. UCB Virtual Briefing [Internet]. 2024 [cited 2025 May 22]. Available from: https:\/\/www.ucb.com\/sites\/default\/files\/2024-10\/240930_ucb_capital_market_call-bimzelx-hs.pdf"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.3655"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.040"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae442"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2021.1967748"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00126-4"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2218086"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223595"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224803"},{"key":"e_1_3_6_33_1","unstructured":"FDA. BIMZLEX FDA SmPC [Internet]. BIMZLEX FDA SmPC. 2025 [cited 2025 Feb 15]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761151s010lbl.pdf"},{"key":"e_1_3_6_34_1","unstructured":"European Medicines Agency. European Medicines Agency Summary of Products Characteristics [Internet]. 2024 [cited 2025 Feb 15]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bimzelx-epar-product-information_en.pdf"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2905"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15102450"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00101-6"},{"key":"e_1_3_6_38_1","unstructured":"UCB Pharma (UCB Biopharma SRL) (Responsible Party). A study to test the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (BE HEARD EXT) [Internet]. 2024 [cited 2024 Nov 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04901195"},{"key":"e_1_3_6_39_1","unstructured":"UCB. BIMZELX[\u00ae]\u25bc(bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in hidradenitis suppurativa (HS) [Internet]. 2025 [cited 2025 Feb 15]. Available from: https:\/\/www.ucb.com\/newsroom\/press-releases\/article\/bimzelxrvbimekizumab-two-year-data-at-ehsf-2025-demonstrate-sustained-disease-control-in-hidradenitis-suppurativa-hs"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00880-1"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16246"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.371"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1727439"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071485"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1586\/eci.09.18"},{"key":"e_1_3_6_46_1","unstructured":"European Medicines Agency. Bimzelx [Internet]. 2024 [cited 2024 Nov 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bimzelx"},{"key":"e_1_3_6_47_1","unstructured":"European Medicines Agency. Assessment report bimzelx International non-proprietary name: bimekizumab procedure No. EMEA\/H\/C\/005316\/II\/0020 [Internet]. 2024 [cited 2025 May 23]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/bimzelx-h-c-005316-ii-0020-epar-assessment-report-variation_en.pdf"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2024.2401308"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/21501203.2023.2265664"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20369"},{"key":"e_1_3_6_51_1","article-title":"Bimekizumab: network meta-analysis to establish comparative efficacy in moderate-to-severe hidradenitis suppurativa patients [Internet]","author":"Naik H","year":"2024","unstructured":"Naik H, Davis L, M\u00f8rup MF, et al. Bimekizumab: network meta-analysis to establish comparative efficacy in moderate-to-severe hidradenitis suppurativa patients [Internet]. Conf Poster. 2024 [cited 2024 Nov 14]. Available from: https:\/\/www.ucbcompass.com\/sites\/default\/files\/2024-10\/EADV24_NMA%20Weeks%2012-16%20in%20HS_20Sep24Submission.pdf","journal-title":"Conf Poster"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/12034754241300292"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2025.2522119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T08:26:00Z","timestamp":1758529560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2025.2522119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,3]]}},"alternative-id":["10.1080\/14712598.2025.2522119"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2025.2522119","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}